Celldex Therapeutics, Inc. (CLDX) quarterly income statement — complete revenue, gross profit & net income history
| Sales/Revenue | 15K | 75K | 0 | 730K | 695K | 1.18M | 3.19M | 2.5M | 156K | 4.13M | 1.52M | 268K |
| Revenue Growth % | -97.84% | -93.62% | -100% | -70.78% | 345.51% | -71.56% | 110.35% | 832.09% | -83.87% | 156.11% | 272.73% | 64.42% |
| Cost of Goods Sold | 854K | 0 | 0 | 0 | 0 | 819K | 0 | 797K | 775K | 30.43M | 767K | 26.25M |
| COGS % of Revenue | 5693.33% | - | - | - | - | 69.7% | - | 31.91% | 496.79% | 736.53% | 50.56% | 9795.52% |
| Gross Profit | -839K | 75K | 0 | 730K | 695K | 356K | 3.19M | 1.7M | -619K | -26.3M | 750K | -25.98M |
| Gross Margin % | -5593.33% | 100% | - | 100% | 100% | 30.3% | 100% | 68.09% | -396.79% | -636.53% | 49.44% | -9695.52% |
| Gross Profit Growth % | -220.72% | -78.93% | -100% | -57.08% | 212.28% | 101.35% | 325.47% | 106.55% | 97.6% | -23.53% | 103.54% | -26.33% |
| Operating Expenses | 83.6M | 87.26M | 73.62M | 64.59M | 63.43M | 56.38M | 55.32M | 48.02M | 39.99M | 21.33M | 41.99M | 7.22M |
| OpEx % of Revenue | 557306.67% | 116349.33% | - | 8847.53% | 9127.19% | 4798.55% | 1733.53% | 1922.26% | 25633.97% | 516.39% | 2767.9% | 2694.4% |
| Selling, General & Admin | 11.45M | 11.9M | 10.69M | 10.39M | 10.82M | 10.26M | 10.05M | 9.13M | 9.1M | 8.83M | 8.22M | 7.22M |
| SG&A % of Revenue | 76326.67% | 15870.67% | - | 1423.42% | 1556.83% | 873.45% | 315.07% | 365.41% | 5835.26% | 213.8% | 541.92% | 2694.4% |
| Research & Development | 73M | 75.36M | 62.93M | 54.2M | 52.61M | 46.12M | 3K | 38.89M | 30.89M | 30.43M | 34.53M | 26.25M |
| R&D % of Revenue | 486673.33% | 100478.67% | - | 7424.11% | 7570.36% | 3925.11% | 0.09% | 1556.85% | 19798.72% | 736.53% | 2276.53% | 9795.52% |
| Other Operating Expenses | -854K | 0 | 0 | 0 | 0 | 0 | 1000K | 0 | 0 | -1000K | -767K | -1000K |
| Operating Income | -84.44M | -87.19M | -73.62M | -63.86M | -62.74M | -56.03M | -52.13M | -46.32M | -40.61M | -47.63M | -41.24M | -33.2M |
| Operating Margin % | -562900% | -116249.33% | - | -8747.53% | -9027.19% | -4768.26% | -1633.53% | -1854.16% | -26030.77% | -1152.92% | -2718.46% | -12389.93% |
| Operating Income Growth % | -34.58% | -55.62% | -41.23% | -37.87% | -54.5% | -17.64% | -26.4% | -39.49% | -25.06% | -70.8% | -48.9% | 8.77% |
| EBITDA | -83.58M | -86.37M | -72.79M | -62.98M | -61.87M | -55.21M | -51.34M | -45.52M | -39.83M | -46.87M | -40.47M | -32.45M |
| EBITDA Margin % | -557206.67% | -115161.33% | - | -8627.95% | -8902.45% | -4698.55% | -1608.9% | -1822.26% | -25533.97% | -1134.54% | -2667.9% | -12107.84% |
| EBITDA Growth % | -35.09% | -56.45% | -41.79% | -38.37% | -55.33% | -17.79% | -26.85% | -40.28% | -25.48% | -72.23% | -49.76% | 8.99% |
| D&A (Non-Cash Add-back) | 854K | 816K | 824K | 873K | 867K | 819K | 786K | 797K | 775K | 759K | 767K | 756K |
| EBIT | -84.44M | -81.36M | -73.62M | -63.86M | -62.74M | -56.03M | -52.13M | -46.32M | -40.61M | -35.13M | -41.24M | -33.2M |
| Net Interest Income | 5.75M | 5.84M | 6.57M | 7.26M | 8.94M | 8.94M | 10.01M | 10.47M | 7.8M | 1.21M | 2.98M | 2.7M |
| Interest Income | 5.75M | 5.84M | 6.57M | 7.26M | 8.94M | 8.94M | 10.01M | 10.47M | 7.8M | 4.32M | 2.98M | 2.7M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3.11M | 0 | 0 |
| Other Income/Expense | 5.75M | 5.83M | 6.57M | 7.26M | 8.94M | 8.94M | 10.01M | 10.47M | 7.8M | 4.32M | 2.98M | 2.7M |
| Pretax Income | -78.69M | -81.36M | -67.04M | -56.6M | -53.8M | -47.09M | -42.12M | -35.84M | -32.81M | -43.31M | -38.26M | -30.5M |
| Pretax Margin % | -524566.67% | -108480% | - | -7753.42% | -7740.43% | -4007.83% | -1319.99% | -1434.83% | -21030.77% | -1048.32% | -2522.08% | -11381.34% |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -78.69M | -81.36M | -67.04M | -56.6M | -53.8M | -47.09M | -42.12M | -35.84M | -32.81M | -43.31M | -38.26M | -30.5M |
| Net Margin % | -524566.67% | -108480% | - | -7753.42% | -7740.43% | -4007.83% | -1319.99% | -1434.83% | -21030.77% | -1048.32% | -2522.08% | -11381.34% |
| Net Income Growth % | -46.27% | -72.77% | -59.17% | -57.92% | -63.97% | -8.74% | -10.09% | -17.51% | -11.74% | -63.5% | -42.85% | 15.28% |
| Net Income (Continuing) | -78.69M | -81.36M | -67.04M | -56.6M | -53.8M | -47.09M | -42.12M | -35.84M | -32.81M | -43.31M | -38.26M | -30.5M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -1.18 | -1.23 | -1.01 | -0.85 | -0.81 | -0.71 | -0.64 | -0.54 | -0.56 | -0.83 | -0.81 | -0.65 |
| EPS Growth % | -45.68% | -73.24% | -57.81% | -57.41% | -44.64% | 14.46% | 20.99% | 16.92% | 9.68% | -48.21% | -42.11% | 15.58% |
| EPS (Basic) | -1.18 | -1.23 | -1.01 | -0.85 | -0.81 | -0.71 | -0.64 | -0.54 | -0.56 | -0.83 | -0.81 | -0.65 |
| Diluted Shares Outstanding | 66.57M | 66.5M | 66.42M | 66.39M | 66.38M | 66.35M | 66.29M | 66.02M | 58.87M | 52.03M | 47.26M | 47.25M |
| Basic Shares Outstanding | 66.57M | 66.5M | 66.42M | 66.39M | 66.38M | 66.35M | 66.29M | 66.02M | 58.87M | 52.03M | 47.26M | 47.25M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - | - | - |